Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Targeting LRRC15 expressing fibroblasts holds therapeutic potential to ameliorate inflammation and fibrosis in autoimmune diseases.

Created on 24 Jun 2026

Authors

Xintao Tu, Thao-Nguyen Bach, Arjun Baghela, Mark Ziestorff, William Smallridge, Qian Chen, Soha Motlagh, Travis Barr, Marc Sze, In Sock Jang, Jie Zhang-Hoover, Alex Tamburino, Vanessa Peterson, Rajesh Kamath, Marc C Levesque, Karin Vroom, Nidhi Malhotra

Published in

Rheumatology (Oxford, England). Jun 24, 2026. Epub Jun 24, 2026.

Abstract

Targeting stromal cells such as inflammatory fibroblasts presents a potential avenue to alleviate autoimmune inflammation and fibrosis. This study aimed to characterize LRRC15 expression in Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) across fibroblast subsets and assess whether targeting LRRC15 expressing fibroblasts can be beneficial for the treatment of fibrosis and fibroblast-mediated inflammation.
We conducted transcriptomic analyses of Lrrc15 in bulk and single-cell RNA-seq datasets from RA and SSc. We used flow cytometry, RNA-seq, immunohistochemistry and spatial transcriptomics to define Lrrc15 expression patterns in diseased tissues. We performed in vitro and in vivo assays to elucidate the function of LRRC15 in inflammatory fibroblasts.
When compared with healthy controls, we observed a higher activated fibroblast gene signature in RA synovium and SSc skin biopsies that correlated with Lrrc15 expression. Multi-IF imaging highlighted the clustering of LRRC15 expressing fibroblasts within tertiary lymphoid structures (TLS) in RA synovium. Knock down of Lrrc15 in primary cells reduced production of TNF-α induced inflammatory chemokines including CCL3 and CXCL10. We confirmed LRRC15 upregulation in mouse models of wound healing and pulmonary fibrosis. Inflammatory fibroblasts with high LRRC15 expression were susceptible to NK cell-mediated LRRC15 specific lysis in vitro.
Targeting LRRC15+ fibroblasts and fibrotic microenvironment may offer a new therapeutic opportunity to reduce inflammation in RA, SSc and other autoimmune disorders where activated fibroblasts play a role in disease pathogenesis.

PMID:
42340684
Bibliographic data and abstract were imported from PubMed on 24 Jun 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement